Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 8/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.45 |
| ▸ | IL1B | P01584 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383200 | 0.91 | CRBN (0.61) | CRBNIKZF3DDB1MAP1LC3BSTAT3 | |
| SCHEMBL25627634 | 0.83 | CRBN (0.52) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL13464192 | 0.83 | DDB1 (0.67) | CRBNIKZF3DDB1STAT3IKZF1 | |
| SCHEMBL16768290 | 0.82 | CRBN (0.66) | CRBNIKZF3DDB1IKZF1TNF | |
| SCHEMBL21602724 | 0.82 | CRBN (0.51) | CRBNIKZF3DDB1MAP1LC3BSTAT3 | |
| SCHEMBL13464213 | 0.81 | CRBN (0.57) | CRBNIKZF3DDB1MAP1LC3BSTAT3 | |
| SCHEMBL476989 | 0.80 | CRBN (0.68) | CRBNIKZF3DDB1MAP1LC3BSTAT3 | |
| SCHEMBL13464245 | 0.80 | CRBN (0.61) | CRBNIKZF3DDB1MAP1LC3BSTAT3 | |
| SCHEMBL26317784 | 0.80 | CRBN (0.68) | CRBNIKZF3DDB1MAP1LC3BSTAT3 | |
| SCHEMBL17724166 | 0.79 | CRBN (0.62) | CRBNIKZF3DDB1STAT3IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286986-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | TNF, IKZF3, TNFRSF1A | CRBN 1695/4885IKZF3 2/4885DDB1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.